CN101450120A - Medicine composition for treating melancholia using ginseng, Chinese date as raw material and preparation method thereof - Google Patents
Medicine composition for treating melancholia using ginseng, Chinese date as raw material and preparation method thereof Download PDFInfo
- Publication number
- CN101450120A CN101450120A CNA2007101946805A CN200710194680A CN101450120A CN 101450120 A CN101450120 A CN 101450120A CN A2007101946805 A CNA2007101946805 A CN A2007101946805A CN 200710194680 A CN200710194680 A CN 200710194680A CN 101450120 A CN101450120 A CN 101450120A
- Authority
- CN
- China
- Prior art keywords
- extract
- fructus jujubae
- pharmaceutical composition
- radix ginseng
- adenosine monophosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a group of pharmaceutical compositions for treating melancholia made from the raw materials including Ginseng and jujube. The invention further discloses the preparation method of the pharmaceutical compositions. Experiments proves that: the pharmaceutical composition of the invention can obviously reduce the tail suspension time and the forced swimming cumulative immobility time of the tested mice, which proves that it achieves anti-melancholia function.
Description
Technical field
The present invention relates to Radix Ginseng, Fructus Jujubae be raw material make be used for the treatment of hypochondriacal pharmaceutical composition, it can be used as medicine, nutrient and health food.The invention still further relates to the above-mentioned hypochondriacal preparation of drug combination method that is used for the treatment of.
Background technology
The melancholia is a kind of common disease, and nearly 25% women lives through the melancholia in life at it in general population according to statistics, has about 10% to live through melancholia's (Zhang Chunxing work: " pop psychology ") among the male approximately.The data that The World Health Organization (WHO) provides: the melancholia is about 11% at global sickness rate, the whole world has 3.4 hundred million depressed patients approximately at present, and this numeral still becomes ascendant trend, and investigation finds that the melancholia will rise to world's second largest common disease at 20 years from now on.
In the prior art, Remeron is based on fluoxetine, seroxat, Zoloft etc. (5-HT, NE, the DA reuptake inhibitors of classes such as SSRI, SNRI, NDRI), and its mechanism of action is to alleviate melancholy symptom by component contents such as 5-hydroxy tryptamine in the increase human nerve medium.
But, the Remeron of having asked the city all has side effect in various degree, for example: increase homicide rate, headache, dizziness, dizzy, insomnia, drowsiness, tinnitus, xerostomia, anorexia, appetite increases, body weight rising, increased blood pressure, gastrointestinal upset, regurgitation, nauseating, vomiting, dyspepsia, diarrhoea, constipation, leg pain, skin eruption, tremble, spasm, hyperhidrosis, edema, libido reduction, sexual dysfunction etc.Remeron such as fluoxetine has become the serious problem of paying close attention to of society in recent years, U.S. food and FAD (Food and Drug Administration, FDA) more in required in 2004 the pharmaceutical factory with market on 32 kinds of main Remerons indicate the part of its side effect and warning again, and medical personnel are emphasized that these medicines may increase the probability that child and teenager are committed suiside.Wherein, seroxat just was found as far back as 1996 especially and has potential safety hazard, began to recall from the market successively from calendar year 2001.In June, 2004, the New York, United States chief procurator accuses Britain GlaxoSmithKline PLC company in order to obtain profit, and fraudulence has been concealed and taken related research report between seroxat and " increasing the risk of teenager suicidal tendency and behavior ".Under this background, how to research and develop the problem that the low medicine that obviously anti-melancholy effect can be arranged again of side effect of new generation has become global the world of medicine and paid close attention to.
In recent years, the scientists of international the world of medicine new breakthrough occurring aspect the research of melancholia's pathogenesis, discovery is except the reuptake suppressor mode treatment melancholia with 5-HT, NE, DA, more can take to regulate behind the receptor mode of mechanism of action and treat the melancholia, and owing to mechanism of action behind the receptor is regulated the class medicine and enumerated the research and development focus that the appearance of pula (Rolipram) becomes the world of medicine's Remeron.Enumerating the pula is that (phosphodiesterase 4 for four type phosphodiesterases, PDE4) inhibitor, clinical trial shows that it has significantly anti-melancholy effect, but enumerate the pula and strong vomiting can occur owing to take, so be forced to stop research and development, yet enumerate the research and development thinking that a new generation's " mechanism of action Remeron behind the receptor " has but been opened up in the pula.
In sum, the applicant is after having understood the limitation that is had in the known technology, through concentrated research and discovery, and in line with the spirit of working with perseverance, finally having found " is hypochondriacal pharmaceutical composition of raw material for treating and method for making thereof with Radix Glycyrrhizae, Fructus Jujubae " of the present invention, below is brief description of the present invention.
Bright content
In order to overcome the deficiency of existing pharmaceutical preparation, the inventor is in conjunction with modern medicine and Chinese medicine is treated hypochondriacal pathogenesis to pharmacology's theory and the mechanism of action is studied, on this basis, the inventor proposes the present invention, its purpose be to provide a kind of with Radix Ginseng, Fructus Jujubae be raw material made be used for the treatment of hypochondriacal pharmaceutical composition or health food.The characteristics of this pharmaceutical composition are that the effective component and the mechanism of action are clear and definite, and main functional component can quantize, so steady quality, and curative effect is obvious, and is safe, taking convenience.
It is the made preparation method that is used for the treatment of hypochondriacal pharmaceutical composition or health food of raw material with Radix Ginseng, Fructus Jujubae that another object of the present invention provides above-mentioned.
The solution of medicine of the present invention is the result who concentrates on studies and explore through the inventor, treat hypochondriacal pathology and pharmacology's theory according to modern medicine, particularly mechanism of action antidepressant drug target research behind the bind receptor, prove through a large amount of zooperies: the ginsenoside is contained adenyl cyclase (adenylate cyclase, AC) stimulate adenosine, and contain the inhibition composition of cAMP phosphodiesterase (CAPD); Fructus Jujubae cAMP can improve the expression of human body cAMP, the Fructus Jujubae cAMP of content in the Fructus Jujubae atomic (about ten thousand/) is extracted and purified into the Fructus Jujubae extract that contains 1% Fructus Jujubae cAMP resists the zooperal result of tentative depressed effect to show, have significantly anti-tentative depressed function, the Fructus Jujubae extract that normally contains micro-Fructus Jujubae cAMP does not then have significantly anti-tentative depressed function; The ginsenoside, the two compatibility of Fructus Jujubae cAMP, synergism, can further improve availability and the activity of cAMP, and the concentration of cAMP and increased activity, then can increase norepinephrine (norepinephrine, NE) etc. neurotransmitter synthetic with discharge, strengthen Brain Derived Neurotrophic Factor (brain-derived neurotrophic factor, BDNF) expression, suppress hypothalmus-pituitary-adrenal axis (hypothalamic-pituitary-adrenal axis, the secretion of hyperfunction and glucocorticoid hpa axis), thus reach significant anti-melancholy function.Radix Ginseng, Fructus Jujubae have been the traditional Chinese medical science and tonic medicated diet medical material and food commonly used since several thousand, in edible and clinical use in 1,100, fully prove the safety of Radix Ginseng, the two compatibility of Fructus Jujubae, side effect such as strong vomiting can not take place and take Radix Ginseng and Fructus Jujubae, so it is raw material that the inventor proposes with Radix Ginseng and Fructus Jujubae, make and be used for the treatment of hypochondriacal oral drugs or health food, particularly effective component is clear and definite, take safely for a long time, the new solution that can not cause side effect such as strong vomiting is to improve the weak point that is had in the known technology.
In order to finish purpose of the present invention, the following technical scheme of special proposition.
The present invention has disclosed a kind of hypochondriacal pharmaceutical composition that is used for the treatment of, and described pharmaceutical composition is made by the raw material that comprises Radix Ginseng, Fructus Jujubae.
Preferably, pharmaceutical composition of the present invention is made by the raw material of the Fructus Jujubae of Radix Ginseng that comprises 4～62 weight portions and 2～42 weight portions.
Preferably, pharmaceutical composition of the present invention is made by the raw material of the Fructus Jujubae of Radix Ginseng that comprises 10～30 weight portions and 4～20 weight portions.
According to another notion of the present invention, the present invention has disclosed a kind of hypochondriacal pharmaceutical composition that is used for the treatment of, and described pharmaceutical composition is made by the raw material that comprises Radix Ginseng, Fructus Jujubae extraction extract.
Preferably, pharmaceutical composition of the present invention is made by the raw material of the Fructus Jujubae extraction extract that comprises the Radix Ginseng extraction extract that contains 4～62 weight portion ginsenosides (Rg1+Rb1) and contain 0.01～0.2 weight portion Fructus Jujubae cyclic adenosine monophosphate.
Preferably, pharmaceutical composition of the present invention is made by comprising the Radix Ginseng extract that contains 12～36 weight portion ginsenosides (Rg1+Rb1) and containing the raw material of Fructus Jujubae extract of 0.024～0.12 weight portion Fructus Jujubae cyclic adenosine monophosphate.
Preferably, used Fructus Jujubae extract is the second following extract in the pharmaceutical composition of the present invention: extract Fructus Jujubae earlier and obtain first extract, described first extract of repurity gets second extract; The Fructus Jujubae cyclic adenosine monophosphate of wherein said second extract (Fructus Jujubae cyclic adenosinemonophosphate, Fructus Jujubae cAMP) concentration is higher than the Fructus Jujubae cyclic adenosine monophosphate concentration of described first extract.
According to another notion of the present invention, the present invention has disclosed a kind of hypochondriacal preparation of drug combination method that is used for the treatment of, and comprises the following steps:
(a) extract the extract of winning with heating with alcoholic solution or water after the Radix Ginseng fragmentation of 4～62 weight portions, to get second extract behind the column chromatographic isolation and purification on described first extract, the ginsenoside of wherein said second extract (Rg1+Rb1) concentration is higher than ginsenoside (Rg1+Rb1) concentration of described first extract;
(b) water after the Fructus Jujubae fragmentation of 2～42 weight portions is heated extract the extract of winning, to get second extract behind the column chromatographic isolation and purification on described first extract, the Fructus Jujubae cyclic adenosine monophosphate concentration of wherein said second extract is higher than the Fructus Jujubae cyclic adenosine monophosphate concentration of described first extract; And
(c) Radix Ginseng second extract and Fructus Jujubae second extract with step (a) and step (b) gained mixes pulverizing, promptly gets pharmaceutical composition of the present invention.
Preferably, pharmaceutical composition of the present invention can be processed into dosage form, and this dosage form is selected from one of oral Pharmaceutical dosage forms on lozenge, capsule, powder, tablet, powder, solution, microcapsule, suspensoid, Emulsion, granule, drop pill, pill and the pharmaceutics.
Preferably, pharmaceutical composition of the present invention can comprise pharmaceutically acceptable carrier or additive.
Preferably, pharmaceutical composition of the present invention also can be used to make health food and nutrient.
Above-mentioned pharmaceutical composition is a core prescription of realizing the object of the invention, and after the present invention was open, those skilled in the art can carry out conventional adding to aforementioned pharmaceutical compositions and simplify sanction according to theory of Chinese medical science or relevant modern pharmacology theory.The adding of this routine simplifies and cut out is those skilled in the art's general technical activity, so long as the general technology plus-minus that on the prescription basis of pharmaceutical composition of the present invention, is carried out, all within protection scope of the present invention.
Can understand the present invention better by consulting accompanying drawing and describing in detail.
Summary of drawings
Fig. 1 is the method flow sketch map of the preparation embodiment of the invention 1 medicine.
Fig. 2 is the method flow sketch map of the preparation embodiment of the invention 2 medicines.
Better embodiment of the present invention
Further specify the present invention below with reference to drawings and Examples.The present invention adopts to well known to a person skilled in the art that method prepares medicine of the present invention in conjunction with feature of the present invention.Following examples only are in order to illustrate, and non-limiting the present invention.
In order to finish purpose of the present invention, the following technical scheme of the special proposition of the present invention.
Scheme one:
Make the present invention with the raw material that comprises Radix Ginseng, Fructus Jujubae and be used for the treatment of hypochondriacal pharmaceutical composition.
Scheme two:
Make the present invention with the raw material of the Fructus Jujubae of the Radix Ginseng that comprises 4～62 weight portions and 2～42 weight portions and be used for the treatment of hypochondriacal pharmaceutical composition.
Scheme three:
Make the present invention with the raw material of the Fructus Jujubae of the Radix Ginseng that comprises 10～30 weight portions and 4～20 weight portions and be used for the treatment of hypochondriacal pharmaceutical composition.
Scheme four:
Make the present invention with the raw material that comprises Radix Ginseng extract and Fructus Jujubae extract and be used for the treatment of hypochondriacal pharmaceutical composition.
Scheme five:
Make the present invention with the raw material that comprises the Radix Ginseng extract that contains 4～62 weight portion ginsenosides (Rg1+Rb1) and contain the Fructus Jujubae extract of 0.01～0.2 weight portion Fructus Jujubae cyclic adenosine monophosphate and be used for the treatment of hypochondriacal pharmaceutical composition.
Scheme six:
Make the present invention with the raw material that comprises the Radix Ginseng extract that contains 12～36 weight portion ginsenosides (Rg1+Rb1) and contain the Fructus Jujubae extract of 0.024～0.12 weight portion Fructus Jujubae cyclic adenosine monophosphate and be used for the treatment of hypochondriacal pharmaceutical composition.
Scheme seven:
The present invention program's four described Fructus Jujubae extracts are second following extracts: extract Fructus Jujubae earlier and obtain first extract, described first extract of repurity gets second extract; The Fructus Jujubae cyclic adenosine monophosphate concentration of wherein said second extract is higher than the Fructus Jujubae cyclic adenosine monophosphate concentration of described first extract.
Scheme eight:
With the preparation method that comprises the following steps, make the present invention and be used for the treatment of hypochondriacal pharmaceutical composition:
(a) after the Radix Ginseng fragmentation with 4～62 weight portions, heat with alcoholic solution or water and to extract the extract of winning, to get second extract behind the column chromatographic isolation and purification on described first extract, the ginsenoside of wherein said second extract (Rg1+Rb1) concentration is higher than ginsenoside (Rg1+Rb1) concentration of described first extract;
(b) after the Fructus Jujubae fragmentation with 2～42 weight portions, heat with water and to extract the extract of winning, to get second extract behind the column chromatographic isolation and purification on described first extract, the Fructus Jujubae cyclic adenosine monophosphate concentration of wherein said second extract is higher than the Fructus Jujubae cyclic adenosine monophosphate concentration of described first extract; And
(c) Radix Ginseng second extract and Fructus Jujubae second extract with step (a) and step (b) gained mixes pulverizing, promptly gets pharmaceutical composition of the present invention.
Scheme nine:
Pharmaceutical composition of the present invention can be processed into dosage form, and this dosage form is selected from one of oral Pharmaceutical dosage forms on lozenge, capsule, powder, tablet, powder, solution, microcapsule, suspensoid, Emulsion, granule, drop pill, pill and the pharmaceutics.
Scheme ten:
Pharmaceutical composition of the present invention can comprise pharmaceutically acceptable carrier or additive.
Scheme 11:
Pharmaceutical composition of the present invention also can be used to make health food and nutrient.
In order to finish purpose of the present invention, the process for preparing medicine below special the proposition.
Method one:
The raw material that will comprise Radix Ginseng, Fructus Jujubae is processed into the present invention and is used for the treatment of hypochondriacal pharmaceutical composition.
Method two:
To comprise the raw material of the Fructus Jujubae of the Radix Ginseng of 4～62 weight portions and 2～42 weight portions, and be processed into the present invention and be used for the treatment of hypochondriacal pharmaceutical composition.
Method three:
To comprise the raw material of the Fructus Jujubae of the Radix Ginseng of 10～30 weight portions and 4～20 weight portions, and be processed into the present invention and be used for the treatment of hypochondriacal pharmaceutical composition.
Method four:
The raw material that will comprise Radix Ginseng extract and Fructus Jujubae extract is processed into the present invention and is used for the treatment of hypochondriacal pharmaceutical composition.
Method five:
To comprise Radix Ginseng extract that contains 4～62 weight portion ginsenosides (Rg1+Rb1) and the raw material that contains the Fructus Jujubae extract of 0.01～0.2 weight portion Fructus Jujubae cyclic adenosine monophosphate, and be processed into the present invention and be used for the treatment of hypochondriacal pharmaceutical composition.
Method six:
To comprise Radix Ginseng extract that contains 12～36 weight portion ginsenosides (Rg1+Rb1) and the raw material that contains the Fructus Jujubae extract of 0.024～0.12 weight portion Fructus Jujubae cyclic adenosine monophosphate, and be processed into the present invention and be used for the treatment of hypochondriacal pharmaceutical composition.
Method seven:
Method four described Fructus Jujubae extracts are second following extracts: extract Fructus Jujubae earlier and obtain first extract, described first extract of repurity gets second extract; The Fructus Jujubae cyclic adenosine monophosphate concentration of wherein said second extract is higher than the Fructus Jujubae cyclic adenosine monophosphate concentration of described first extract.
Method eight:
With the preparation method that comprises the following steps, make the present invention and be used for the treatment of hypochondriacal pharmaceutical composition:
(a) extract the extract of winning with heating with alcoholic solution or water after the Radix Ginseng fragmentation of 4～62 weight portions, to get second extract behind the column chromatographic isolation and purification on described first extract, the ginsenoside of wherein said second extract (Rg1+Rb1) concentration is higher than ginsenoside (Rg1+Rb1) concentration of described first extract;
(b) water after the Fructus Jujubae fragmentation of 2～42 weight portions is heated extract the extract of winning, to get second extract behind the column chromatographic isolation and purification on described first extract, the Fructus Jujubae cyclic adenosine monophosphate concentration of wherein said second extract is higher than the Fructus Jujubae cyclic adenosine monophosphate concentration of described first extract; And
(c) Radix Ginseng second extract and Fructus Jujubae second extract with step (a) and step (b) gained mixes pulverizing, promptly gets pharmaceutical composition of the present invention.
Method nine:
Pharmaceutical composition of the present invention is processed into dosage form, and this dosage form is selected from one of oral Pharmaceutical dosage forms on lozenge, capsule, powder, tablet, powder, solution, microcapsule, suspensoid, Emulsion, granule, drop pill, pill and the pharmaceutics.
Method ten:
Pharmaceutical composition of the present invention is processed into comprises pharmaceutically acceptable carrier or additive.
Method 11:
Pharmaceutical composition of the present invention is processed into comprises health food and nutrient.
Specific embodiment
Further specify the present invention below with reference to the drawings and specific embodiments.
Embodiment 1
See also Fig. 1, it is the method flow sketch map of the preparation embodiment of the invention 1 medicine.In Fig. 1, with the Radix Ginseng fragmentation of 10kg, with 70% alcoholic solution heat extract Radix Ginseng extract, again with column chromatographic isolation and purification on this Radix Ginseng extract, drying, the Radix Ginseng extract of 0.4kg (contains 60g ginsenoside Rg1+Rb1); To add the water soak at room temperature after the fragmentation of 2kg Fructus Jujubae, extract with decoction and alcohol sedimentation technique again and obtain Fructus Jujubae extract, again with this extract macroporous resin OU-2, the successively continuous upper prop adsorbing separation of ME-2 two posts, drying, get the Fructus Jujubae extract (containing 0.06g Fructus Jujubae cAMP) of 6g, the extract obtained mixing of above-mentioned steps is pulverized evenly, promptly get 406g pharmaceutical composition of the present invention.
Embodiment 2
See also Fig. 2, it is the method flow sketch map of the preparation embodiment of the invention 2 medicines.In Fig. 2, the ginsenoside Rb1 that directly will be prepared into purity and be the ginsenoside Rg1 of 90% 1.2g and purity and be 90% 2.8g mixes with the Fructus Jujubae extract 0.8g that contains 8mg Fructus Jujubae cAMP and pulverizes evenly, promptly gets 4.8g extract drugs compositions of the present invention.
The influence of 1 pair of mouse tail suspension experiment of experimental example 1 embodiment
1.1 laboratory animal
The ICR mice, male, body weight 22.0 ± 2g, secondary, the department of the Chinese Academy of Sciences of laboratory animal section of Beijing Capital University of Medical Sciences provides.
1.2 experimental drug
Embodiment 1: Beijing Ounaer B iological Engineering and Technology Co., Ltd. provides.
Paroxetine (seroxat): Sino-America Tianjin Shike Pharmaceutical Co., Ltd.'s product.
1.3 experimental apparatus
Stopwatch.
1.4 dosage design
Embodiment 1 high dose is that 60mg/kg/d, middle dosage are that 30mg/kg/d and low dosage are 15mg/kg/d.
1.5 experimental technique and result
1.5.1 grouping administration
With the mice random packet, 10 every group: 1. embodiment 1 high dose group (60mg/kg, PO, administration 7d); 2. dosage group (30mg/kg, PO, administration 7d) among the embodiment 1; 3. embodiment 1 low dose group (15mg/kg, PO, administration 7d); 4. paroxetine group (3mg/kg, PO, administration 7d); 5. normal saline group (PO).Hang tail in 1 hour after the last administration tests.
1.5.2 experimental technique
Mouse tail (apart from tail point 1cm place) is bonded at head height with adhesive plaster goes out on the batten of table top 5cm to suspend in midair 6 minutes, write down the dead time of mice in back 5 minutes.
1.5.3 statistical procedures
Experimental data represents that with X ± SD experimental result is carried out variance analysis with SPSS 11.5 statistical softwares.
1.5.4 experimental result
Experimental result sees also table 1.
The influence of table 1,1 pair of mice dead time of embodiment
Annotate: compare with model group
*P＜0.05
*P＜0.01
Conclusion:
According to above experiment, the embodiment of the invention 1 high, medium and low dosage group and paroxetine group all can reduce the dead time after the mouse tail suspension as can be seen, middle dosage has been compared significant difference with low dose group with normal saline group (model group), thereby can infer that the embodiment of the invention 1 has the depressed function of anti-experimental character.
The influence of 1 pair of mice forced swimming experiment of experimental example 2 embodiment
2.1 laboratory animal
The ICR mice, male, body weight 22.0 ± 2g, secondary, the department of the Chinese Academy of Sciences of laboratory animal section of Beijing Capital University of Medical Sciences provides.
2.2 experimental drug
Embodiment 1: Beijing Ounaer B iological Engineering and Technology Co., Ltd. provides.
Paroxetine (seroxat): Sino-America Tianjin Shike Pharmaceutical Co., Ltd.'s product.
2.3 experimental apparatus
Stopwatch.
2.4 dosage design
Embodiment 1 high dose is that 60mg/kg/d, middle dosage are that 30mg/kg/d and low dosage are 15mg/kg/d.
2.5 experimental technique and result
2.5.1 grouping administration
With the mice random packet, 10 every group: 1. embodiment 1 high dose group (60mg/kg, PO, administration 7d); 2. dosage group (30mg/kg, PO, administration 7d) among the embodiment 1; 3. embodiment 1 low dose group (15mg/kg, PO, administration 7d); 4. paroxetine group (3mg/kg, PO, administration 7d); 5. normal saline group (PO).The forced swimming experiment is carried out in last administration after 1 hour.
2.5.2 experimental technique
Mice is put into the glass jar of depth of water 10cm, diameter 14cm respectively, and 25 ℃ of water temperatures are observed the 5 minutes record accumulative total dead times of mice in water.
2.5.3 statistical procedures
Experimental data represents that with X ± SD experimental result is carried out variance analysis with SPSS 11.5 statistical softwares.
2.5.4 experimental result
Experimental result sees also table 2.
The influence of table 2,1 pair of mice dead time of embodiment
Annotate: compare with model group
*P＜0.05
*P＜0.01
Conclusion:
According to above experiment, the embodiment of the invention 1 high, medium and low dosage group and paroxetine group all can obviously shorten the mice forced swimming accumulative total dead time as can be seen, middle dosage group has been compared significant difference with high dose group with normal saline group (model group), thereby can infer that the embodiment of the invention 1 has the depressed function of anti-experimental character.
The present invention is used for the treatment of the range of application of hypochondriacal oral drugs:
1. of the present invention being used for the treatment of in the hypochondriacal oral drugs, can contain on the materia medica Acceptable additive;
2. of the present inventionly be used for the treatment of hypochondriacal oral drugs and it can be processed into diffusing Agent, capsule, tablet, etc. various known formulations; And
3. of the present inventionly be used for the treatment of hypochondriacal oral drugs and can make and be used for the treatment of melancholy The health food of disease.
Those skilled in the art can make various improvement to the present invention, do not want and do not break away from such as appended right The protection domain of asking.
Claims (18)
1. treat hypochondriacal pharmaceutical composition for one kind, it is made by the raw material that comprises Radix Ginseng and Fructus Jujubae.
2. pharmaceutical composition as claimed in claim 1, wherein said pharmaceutical composition are further made by the raw material of the Fructus Jujubae of Radix Ginseng that comprises 4～62 weight portions and 2～42 weight portions.
3. pharmaceutical composition as claimed in claim 2, wherein said pharmaceutical composition are further made by the raw material of the Fructus Jujubae of Radix Ginseng that comprises 10～30 weight portions and 4～20 weight portions.
4. pharmaceutical composition as claimed in claim 1, wherein said medicine contain and are selected from pharmaceutically acceptable carrier, additive and combination thereof.
5. pharmaceutical composition as claimed in claim 1, wherein said pharmaceutical composition is made dosage form, and this dosage form is selected from one of oral Pharmaceutical dosage forms on lozenge, capsule, powder, tablet, powder, solution, microcapsule, suspensoid, Emulsion, granule, drop pill, pill and the pharmaceutics.
6. pharmaceutical composition as claimed in claim 1, wherein said pharmaceutical composition is made health food or nutrient.
7. treat hypochondriacal pharmaceutical composition for one kind, it is made by the raw material that comprises Radix Ginseng extract and Fructus Jujubae extract.
8. pharmaceutical composition as claimed in claim 7, wherein said pharmaceutical composition comprise the described Radix Ginseng extract that contains 4～62 weight portion ginsenosides (Rg1+Rb1) and contain the described Fructus Jujubae extract of 0.01～0.2 weight portion Fructus Jujubae cyclic adenosine monophosphate.
9. pharmaceutical composition as claimed in claim 8, wherein said pharmaceutical composition further comprise the described Radix Ginseng extract that contains 12～36 weight portion ginsenosides (Rg1+Rb1) and contain the described Fructus Jujubae extract of 0.024～0.12 weight portion Fructus Jujubae cyclic adenosine monophosphate.
10. pharmaceutical composition as claimed in claim 7, the wherein said raw material that contains Fructus Jujubae cyclic adenosine monophosphate is the second following extract: extract Fructus Jujubae earlier and obtain first extract, described first extract of repurity gets described second extract, and the Fructus Jujubae cyclic adenosine monophosphate concentration of wherein said second extract is higher than the Fructus Jujubae cyclic adenosine monophosphate concentration of described first extract.
11. containing, pharmaceutical composition as claimed in claim 7, wherein said pharmaceutical composition be selected from pharmaceutically acceptable carrier, additive and combination thereof.
12. pharmaceutical composition as claimed in claim 7, wherein said pharmaceutical composition is made dosage form, and this dosage form is selected from one of oral Pharmaceutical dosage forms on lozenge, capsule, powder, tablet, powder, solution, microcapsule, suspensoid, Emulsion, granule, drop pill, pill and the pharmaceutics.
13. pharmaceutical composition as claimed in claim 7, wherein said pharmaceutical composition is made health food and nutrient.
14. the hypochondriacal preparation of drug combination method of treatment may further comprise the steps:
(a) Radix Ginseng of extraction 4～62 weight portions, the Radix Ginseng extract of winning;
(b) Fructus Jujubae of extraction 2～42 weight portions, the Fructus Jujubae extract of winning;
(c) described first Fructus Jujubae extract of purification gets second Fructus Jujubae extract; And
(d) mix described the first conopsea extraction and described second Fructus Jujubae extract, must this pharmaceutical composition,
The Fructus Jujubae cyclic adenosine monophosphate concentration of wherein said second Fructus Jujubae extract is higher than the Fructus Jujubae cyclic adenosine monophosphate concentration of described first Fructus Jujubae extract.
15. preparation method as claimed in claim 14, wherein step (a) further comprises:
(a1) the described the first conopsea extraction of purification gets second Radix Ginseng extract,
The ginsenoside of wherein said second Radix Ginseng extract (Rg1+Rb1) concentration is higher than ginsenoside (Rg1+Rb1) concentration of described the first conopsea extraction.
16. preparation method as claimed in claim 14, wherein step (c) is selected the Fructus Jujubae cyclic adenosine monophosphate in described first Fructus Jujubae extract of macroporous resin upper prop adsorbing separation that contains aldehyde radical for use.
17. preparation method as claimed in claim 16, wherein step (c) is selected the Fructus Jujubae cyclic adenosine monophosphate in described first Fructus Jujubae extract of macroporous resin OU-2 upper prop adsorbing separation that contains aldehyde radical for use.
18. preparation method as claimed in claim 14, wherein step (c) is separated Fructus Jujubae cyclic adenosine monophosphate in described first Fructus Jujubae extract with macroporous resin ME-2 upper prop again.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101946805A CN101450120A (en) | 2007-11-30 | 2007-11-30 | Medicine composition for treating melancholia using ginseng, Chinese date as raw material and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101946805A CN101450120A (en) | 2007-11-30 | 2007-11-30 | Medicine composition for treating melancholia using ginseng, Chinese date as raw material and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101450120A true CN101450120A (en) | 2009-06-10 |
Family
ID=40732718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101946805A Pending CN101450120A (en) | 2007-11-30 | 2007-11-30 | Medicine composition for treating melancholia using ginseng, Chinese date as raw material and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101450120A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014026341A1 (en) * | 2012-08-15 | 2014-02-20 | 戚郁芬 | Pharmaceutical composition increasing cyclic amp content and availability in vivo, and preparation method thereof |
| WO2021052153A1 (en) * | 2019-09-17 | 2021-03-25 | 中国药科大学 | Application of cyclic adenosine monophosphate, derivatives thereof or prodrugs thereof in preparation of drugs for preventing and/or treating depressive disorder |
-
2007
- 2007-11-30 CN CNA2007101946805A patent/CN101450120A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014026341A1 (en) * | 2012-08-15 | 2014-02-20 | 戚郁芬 | Pharmaceutical composition increasing cyclic amp content and availability in vivo, and preparation method thereof |
| WO2021052153A1 (en) * | 2019-09-17 | 2021-03-25 | 中国药科大学 | Application of cyclic adenosine monophosphate, derivatives thereof or prodrugs thereof in preparation of drugs for preventing and/or treating depressive disorder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2707114C (en) | Pharmaceutical compositions for treating depression and anxiety | |
| CN107126485B (en) | Traditional Chinese medicine composition for assisting in improving sleep and preparation method and application thereof | |
| CN100379436C (en) | Pharmaceutical composition for treating depression, preparation method and application thereof | |
| AU2007361992B2 (en) | Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression | |
| KR20100106324A (en) | Antimelancholic medicine prepared with jujube camp material | |
| CN105853527A (en) | Acer truncatum bunge-containing traditional Chinese medicine composition with sleep improving function and application thereof | |
| CN101450120A (en) | Medicine composition for treating melancholia using ginseng, Chinese date as raw material and preparation method thereof | |
| CN101450103A (en) | Medicine composition for treating hypochondria and anxiety neurosis | |
| CN101450121A (en) | Medicine composition for treating melancholia using glycyrrhiza, Chinese date as raw material and preparation method thereof | |
| CN101450063A (en) | Oral medicine for treating hypochondria | |
| CN113713048A (en) | Solid rhizoma gastrodiae refreshment traditional Chinese medicine composition and preparation method and application thereof | |
| CN104548020B (en) | A kind of purposes of pharmaceutical composition in treatment senile dementia is prepared | |
| CN101450070A (en) | Anti-melancholia medicine using Chinese date Camp as raw material | |
| CN101450062A (en) | Medicine composition for treating melancholia using multi-target receptor after-action mechanism | |
| CN104435298A (en) | Anti-depression pharmaceutical composition | |
| CN105853480A (en) | Application of acer truncatum to making healthcare food or medicine with sleep improving function | |
| CN102153608A (en) | Method for preparing raw material containing Chinese date cyclic adenosine monophosphate of medicinal composition with multi-target receptor afteraction mechanism for treating melancholia | |
| TWI394576B (en) | Pharmaceutical composition produced from ginseng and jujuba for treating depression and manufacturing method thereof | |
| CN103919875A (en) | Method for preparing medicinal composition for treating hypochondria and anxiety | |
| CN101190271A (en) | A set of medicinal compositions for treating melancholia and preparation method | |
| WO2009070923A1 (en) | A pharmaceutical composition for treating melancholy and preparation method thereof | |
| RU2452505C2 (en) | Pharmaceutical compositions with multipurpose receptor reaction mechanism for treating depression | |
| CN115337316A (en) | Application of pharmaceutical composition in 'Junyinnaotong' capsule in treating cerebral apoplexy | |
| CN105687582A (en) | Chinese medicinal composition for preventing and treating senile dementia | |
| TWI453027B (en) | Pharmaceutical having jujuba cyclic adenosine monophosphate as main component for use to treat depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20090610 |